I'm essentially with Vin and 4Seasons on this one. The review can work both ways. It prudently protects Teva's bottom line but is also a great opportunity to fast track. What I am more sceptical about is the time-frame. I'd be surprised if the review takes place as early as 1st quarter 2014 as I'd imagine they would need to follow up on these early patients for at least 6 or 12 months. This is still "early" as a full Phase III normally takes about 3 years. I, of course, hope I'm wrong and that an even earlier review shows such compelling evidence of efficacy that the road to market is fast-tracked but I think we should avoid seeing a delay as bad news.
I'm essentially with Vin and 4Seasons on this one. The review...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.030(1.80%) |
Mkt cap ! $2.172B | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.74 | $1.67 | $6.647M | 3.897M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 44280 | $1.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 26847 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |